Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Pancreatic Cancer Resource Center

News
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024

Allison Casey 

Allison Casey 
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
From Oncology
Quiz
Quiz: Cost of Biosimilar Neutropenia Prophylaxis for Pancreatic Cancer
03/10/2022
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to...
03/10/2022
Journal of Clinical Pathways
News
Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment
02/11/2022

Janelle Bradley

Janelle Bradley
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar...
02/11/2022
Journal of Clinical Pathways
Quiz
Quiz: Educating Patients With Pancreatic Cancer About Treatment Options
02/10/2022
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with...
02/10/2022
Journal of Clinical Pathways
News
Study Identifies Areas for Improvement in Educating Patients With Pancreatic Cancer About Treatment Options
11/03/2021

Marta Rybczynski

Marta Rybczynski
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of...
11/03/2021
Journal of Clinical Pathways
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
Videos
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
02/03/2021
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data...
02/03/2021
Journal of Clinical Pathways
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
Videos
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
01/20/2021
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses...
01/20/2021
Journal of Clinical Pathways
Quiz
Quiz: What Drives Health Care Costs for Patients With Pancreatic Cancer?
09/11/2020
09/11/2020
Journal of Clinical Pathways
News
Outpatient Services Drive Health Care Costs for Patients With Metastatic Pancreatic Cancer
09/10/2020
Study findings show health care costs for patients with metastatic pancreatic ductal adenocarcinoma who received treatment with nab-paclitaxel and gemcitabine or FOLFIRINOX are driven mostly by outpatient costs.
Study findings show health care costs for patients with metastatic pancreatic ductal adenocarcinoma who received treatment with nab-paclitaxel and gemcitabine or FOLFIRINOX are driven mostly by outpatient costs.
Study findings show health care...
09/10/2020
Journal of Clinical Pathways
AGA Updates Clinical Practice Guideline for Pancreatic Cancer Screening
Guideline Updates
AGA Updates Clinical Practice Guideline for Pancreatic Cancer Screening
06/29/2020
Individuals at high risk for pancreatic cancer should at minimum be considered for screening for the disease, according to a new clinical practice update from the American Gastroenterological Association
Individuals at high risk for pancreatic cancer should at minimum be considered for screening for the disease, according to a new clinical practice update from the American Gastroenterological Association
Individuals at high risk for...
06/29/2020
Journal of Clinical Pathways
Research in Review
Pancreatic Cancer Guidelines Do Not Cover Some Targetable Mutations
08/11/2017
JCP Editors
Germline mutations in pancreatic cancer susceptibility genes are often identified in patients with pancreatic cancer without a known family history of cancer, according to a recent study. ----- Related...
Germline mutations in pancreatic cancer susceptibility genes are often identified in patients with pancreatic cancer without a known family history of cancer, according to a recent study. ----- Related...
...
08/11/2017
Journal of Clinical Pathways

Expert Insights

Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
Videos
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
02/03/2021
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data...
02/03/2021
Journal of Clinical Pathways
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
Videos
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
01/20/2021
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses...
01/20/2021
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways

Newsfeed

News
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024

Allison Casey 

Allison Casey 
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
News
Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment
02/11/2022

Janelle Bradley

Janelle Bradley
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar...
02/11/2022
Journal of Clinical Pathways
News
Study Identifies Areas for Improvement in Educating Patients With Pancreatic Cancer About Treatment Options
11/03/2021

Marta Rybczynski

Marta Rybczynski
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of information clinicians need to communicate to patients with pancreatic cancer to help make informed decisions regarding preoperative therapy.
Study identifies key elements of...
11/03/2021
Journal of Clinical Pathways
News
Outpatient Services Drive Health Care Costs for Patients With Metastatic Pancreatic Cancer
09/10/2020
Study findings show health care costs for patients with metastatic pancreatic ductal adenocarcinoma who received treatment with nab-paclitaxel and gemcitabine or FOLFIRINOX are driven mostly by outpatient costs.
Study findings show health care costs for patients with metastatic pancreatic ductal adenocarcinoma who received treatment with nab-paclitaxel and gemcitabine or FOLFIRINOX are driven mostly by outpatient costs.
Study findings show health care...
09/10/2020
Journal of Clinical Pathways
AGA Updates Clinical Practice Guideline for Pancreatic Cancer Screening
Guideline Updates
AGA Updates Clinical Practice Guideline for Pancreatic Cancer Screening
06/29/2020
Individuals at high risk for pancreatic cancer should at minimum be considered for screening for the disease, according to a new clinical practice update from the American Gastroenterological Association
Individuals at high risk for pancreatic cancer should at minimum be considered for screening for the disease, according to a new clinical practice update from the American Gastroenterological Association
Individuals at high risk for...
06/29/2020
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
Conference Coverage
Cybersecurity, Drug Shortages, and PBMs: Legislative Updates Impacting Oncology
04/12/2024

Grace Taylor

Grace Taylor
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry...
04/12/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost of Biosimilar Neutropenia Prophylaxis for Pancreatic Cancer
03/10/2022
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced neutropenia and febrile neutropenia prophylaxis can generate cost-savings for patients with metastatic pancreatic cancer.
True or False: Conversion to...
03/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Educating Patients With Pancreatic Cancer About Treatment Options
02/10/2022
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with pancreatic cancer infrequently hear about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes.
True or False: Patients with...
02/10/2022
Journal of Clinical Pathways
Quiz
Quiz: What Drives Health Care Costs for Patients With Pancreatic Cancer?
09/11/2020
09/11/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement